Lung cancer and scarred lungs: a dangerous duo under the microscope
NCT ID NCT07396467
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor tissue at a cellular level to understand why responses differ.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which lung biopsy method is safer and more accurate?
- Can AI catch lung scarring that doctors might miss?
- Light-Based blood test may spot lung cancer early
- Could a nebulized cocktail make lung scopes less Cough-Inducing?
- Can a JAK inhibitor halt rapid lung decline?
- A personalized approach to breathlessness: could a stepped-care program offer relief for lung cancer patients?